Table 1.
Summary of data obtained by dSTORM and flow cytometry
| # | ID | Flow Cytometry Δ% CD19+ (% anti-CD19 - % isotype) | dSTORM % CD19+ | No of CD19+ cells analyzed by dSTORM | CD19 molecules/ cella CD19+ (range) | CD19 molecules/ cella CD19low | CD19 molecules/ cella CD19high | Elimination by CD19 CAR-T | % IFNγ producing CD19 CAR-T |
|---|---|---|---|---|---|---|---|---|---|
| 1 | M007 | 0 (0.1–0.1) | 0 | – | N/A | N/A | N/A | N/A | 0 |
| 2 | M008 | 0 (1.2–0.9) | 69.2 | 65 | 110 (22–340) | 110 | 0 | + | 4.9 |
| 3 | M011 | (s) (0.8–0.6) | 0 | – | N/A | N/A | N/A | N/A | 0 |
| 4 | M012 | 29 (30.4–1.6) | 67.6 | 34 | 1200 (250–3700) | 750 | 2240 (30%) | + | 8.9 |
| 5 | M013 | 0.9 (1.2–0.3) | 75.1 | 45 | 93 (19–290) | 93 | 0 | + | 0.3 |
| 6 | M014 | 1.7 (4.0–2.3) | 0 | – | N/A | N/A | N/A | N/A | 0 |
| 7 | M015 | (s) (1.1–1.3) | 0 | – | N/A | N/A | N/A | N/A | 0 |
| 8 | M016 | 3.7 (4.9–1.2) | 32.1 | 31 | 530 (110–1650) | 470 | 1850 (4%) | + | 1.2 |
| 9 | M017 | 0 (0.7–1.4) | 66.0 | 20 | 64 (13–200) | 64 | 0 | + | 0.8 |
| 10 | M018 | 0 (0.4–1.7) | 60.4 | 33 | 270 (55–830) | 270 | 0 | + | 0 |
| 11 | M019 | 0 (1.9–2.3) | 80.3 | 25 | 140 (28–420) | 140 | 0 | + | 0.4 |
| 12 | M020 | 2.4 (5.7–2.3) | 46.0 | 36 | 950 (200–3000) | 680 | 2090 (19%) | + | ndt |
| 13 | M021 | 1.3 (3.1–1.8) | 30.2 | 38 | 630 (130–2000) | 530 | 1900 (7%) | + | 0 |
| 14 | M022 | 0.8 (1.5–0.7) | 10.3 | 80 | 1600 (330–5000) | 830 | 2500 (47%) | + | 0 |
(s): single events
ndt cytokine production was not assessed for patient M020
aMean values, in brackets: Calculated data ranging from small (exp (µ−2σ)) to high (exp (µ+2σ)) values (95.45% of all values lie within this range). CD19-positive cells with >1350 molecules per cell were classified as CD19high and were otherwise classified as CD19low (simulated data). Δ% CD19+: the percentage of the cells in the CD19-positive gate for the isotype control was subtracted from the percentage of cells in the CD19-positive gate for the respective CD19 staining